Rigel Pharmaceuticals | RIGL - Lucro Bruto Sobre Vendas





Lucro Bruto Sobre Vendas Alterar Data
Agenus USD 34.2M 4.61M 2025-12
Amgen USD 6.89B 415M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.61B 225M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Celldex Therapeutics USD 121K 609K 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Intrexon USD -297K 167K 2024-06
Ionis Pharmaceuticals USD 243M 48M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
MacroGenics USD 31.11M 30.14M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Pfizer USD 12.28B 8.74B 2025-12
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Veracyte USD 101.97M 10.69M 2025-12